Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI) Stock Overview
Explore Singapore Institute of Advanced Medicine Holdings Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
30.8M
P/E Ratio
-1.05
EPS (TTM)
$-0.03
ROE
-0.38%
9G2.SI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.02.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.05 and a market capitalization of 30.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.
Shih Kien Djeng
107
No. 02-01, 1 Biopolis Drive, Singapore
2024